Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
ALLOPURINOL 300 mg/stuk
Sandoz B.V. Veluwezoom 22 1327 AH ALMERE
M04AA01
ALLOPURINOL 300 mg/stuk
Tablet
LACTOSE 1-WATER ; MAGNESIUMSTEARAAT (E 470b) ; MAÏSZETMEEL ; POVIDON K 30 (E 1201),
Oraal gebruik
Allopurinol
Hulpstoffen: LACTOSE 1-WATER; MAGNESIUMSTEARAAT (E 470b); MAÏSZETMEEL; POVIDON K 30 (E 1201);
2016-11-07
Sandoz B.V. Page 1/8 Allopurinol Sandoz tablet 100 mg / 300 mg, tabletten RVG 117525-6 1313-v8 1.3.1.3 Bijsluiter December 2021 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ALLOPURINOL SANDOZ ® TABLET 100 MG, TABLETTEN ALLOPURINOL SANDOZ ® TABLET 300 MG, TABLETTEN allopurinol READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What [Nationally completed name] is and what it is used for 2. What you need to know before you take [Nationally completed name] 3. How to take [Nationally completed name] 4. Possible side effects 5. How to store [Nationally completed name] 6. Contents of the pack and other information 1. WHAT [NATIONALLY COMPLETED NAME] IS AND WHAT IT IS USED FOR • [Nationally completed name] belongs to a group of medicines called enzyme inhibitors, which act to control the speed at which special chemical changes occur in the body. • [Nationally completed name] is used for the long term, preventative treatment of gout and may be used in other conditions associated with an excess of uric acid in the body, including kidney stones and other types of kidney disease. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE [NATIONALLY COMPLETED NAME] _ _ DO NOT TAKE [NATIONALLY COMPLETED NAME] • if you are allergic to allopurinol or any of the other ingredients of this medicine (listed in section 6). WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking [Nationally completed name] if: • you are of Han Chinese, African or Indian origin Sandoz B.V. Page 2/8 Allopurinol Sandoz tablet 100 mg / Lees het volledige document
Sandoz B.V. Page 1/14 Allopurinol Sandoz tablet 100 mg / 300 mg tabletten RVG 117525-6 1311-V8 1.3.1.1 Samenvatting van de Productkenmerken December 2021 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Allopurinol Sandoz tablet 100 mg, tabletten Allopurinol Sandoz tablet 300 mg, tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION [Nationally completed name] 100 mg tablets Each tablet contains 100 mg of allopurinol. Excipients with known effect Each tablet contains 35 mg of lactose (as monohydrate) [Nationally completed name] 300 mg tablets Each tablet contains 300 mg of allopurinol. Excipients with known effect Each tablet contains 106 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet [Nationally completed name] 100 mg tablets white to off white, scored, flat cylindrical tablet debossed with ‘I’ and ‘56’ on either side of the break line on one side and plain on other side. Diameter: approx. 8 mm. [Nationally completed name] 300 mg tablets white to off white, scored, flat cylindrical tablet debossed with ‘I’ and ‘57’ on either side of the break line on one side and plain on other side. Diameter: approx. 11 mm. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. CLINICAL PARTICULARS Sandoz B.V. Page 2/14 Allopurinol Sandoz tablet 100 mg / 300 mg tabletten RVG 117525-6 1311-V8 1.3.1.1 Samenvatting van de Productkenmerken December 2021 4.1 THERAPEUTIC INDICATIONS Adults • All forms of hyperuricaemia not controllable by diet, including secondary hyperuricaemia of differing origin and clinical complications of hyperuricaemic states, particularly manifest gout, urate nephropathy and for the dissolution and prevention of uric acid stones. • The management of recurrent mixed calcium oxalate stones in concurrent hyperuricaemia, when fluid, dietary and similar measures have failed. Children and adolescents • Secondary hyperuricaemia of differing origin • Uric aci Lees het volledige document